Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

In Partnership With:

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the need for phase 3 data evaluating frontline pembrolizumab (Keytruda) or atezolizumab (Tecentriq) in bladder cancer.

​In 2017, the FDA granted single-agent pembrolizumab and atezolizumab accelerated approvals for the frontline treatment of patients with locally advanced or metastatic bladder cancer who are ineligible for cisplatin-containing chemotherapy. The approvals were based off findings from the phase 2 KEYNOTE-052 (pembrolizumab) and IMvigor210 (atezolizumab) trials.

The agents appear feasible in ​patients with PD-L1–high disease, says Sonpavde. However, phase 3 clinical trials are needed to determine whether the agents are superior to the switch maintenance regimen of gemcitabine/platinum followed by avelumab (Bavencio) maintenance, says Sonpavde.

​The switch maintenance approach is backed by positive phase 3 data from the JAVELIN Bladder 100 trial, concludes Sonpavde.

Related Videos
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS
Michael K. Gibson MD, PhD
Colin E. Champ, MD
Shilpa Gupta, MD
Samer A. Srour, MB ChB, MS
Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania
Alexandra Sokolova, MD
Christie J. Hilton, DO
Yuan Yuan, MD, PhD
Related Content